AstraZeneca: Forxiga recommended for heart failure in the EU
(CercleFinance.com) - AstraZeneca's Forxiga has been recommended by the European Union's Committee for Medicinal Products for Human Use (CHMP) for the treatment of heart failure, which paves the way for potential approval.
Forxiga has been recommended for an indication extension regarding the treatment of symptomatic chronic heart failure with reduced ejection fraction in adults with and without type-2 diabetes, the drugmaker said.
Heart failure, a life-threatening chronic disease in which the heart cannot pump enough blood around the body, affects about 15 million people in Europe, AstraZeneca said.
The company said that the triple-combination therapy Trixeo Aerosphere has also been recommended by the CHMP for marketing authorisation in the EU for maintenance treatment in adult patients with moderate-to-severe chronic obstructive pulmonary disease (COPD).
The European Commission generally follows the recommendation made by the CHMP, which reviews applications for all EU member states.
Copyright (c) 2020 CercleFinance.com. All rights reserved.